Recombinant Human IL28A protein

中文名： 白介素28A(IL28A)重组蛋白
别名： IL28A；IL28A；ZCYTO20；；Interferon lambda-2

货号: PA2000-180DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	IL28A
Uniprot No	Q8IZJ0
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	26-200aa
氨基酸序列	VPVARLHGALPDARGCHIAQFKSLSPQELQAFKRAKDALEESLLLKDCRC HSRLFPRTWDLRQLQVRERPMALEAELALTLKVLEATADTDPALVDVLDQ PLHTLHHILSQFRACIQPQPTAGPRTRGRLHHWLYRLQEAPKKESPGCLE ASVTFNLFRLLTRDLNCVASGDLCV
预测分子量	20 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是与IL28A(IFN-λ1)重组蛋白相关的3篇代表性文献摘要示例，供参考：

---

1. **标题**：*Interferon-λ1 (IL-28A) therapy for chronic hepatitis C: A randomized controlled trial*

**作者**：Marcellin P. et al.

**摘要**：该研究评估了重组IL28A蛋白联合利巴韦林治疗慢性丙型肝炎的疗效，结果显示其可显著降低病毒载量，且副作用少于传统IFN-α疗法，提示IL28A可能成为替代性抗病毒治疗策略。

---

2. **标题**：*Expression and functional characterization of recombinant human IL-28A in mammalian cells*

**作者**：Dellgren C. et al.

**摘要**：报道了通过哺乳动物细胞表达系统高效生产具有生物活性的重组IL28A蛋白，验证其通过激活JAK-STAT通路诱导ISGs(干扰素刺激基因)表达的能力，并证实其对肝癌细胞的抗增殖作用。

---

3. **标题**：*IL-28A enhances antiviral immunity by synergizing with IL-10 in dendritic cells*

**作者**：Wang Y. et al.

**摘要**：研究发现重组IL28A蛋白可增强树突状细胞的抗原呈递功能，并通过与IL-10协同作用抑制流感病毒复制，揭示了其作为免疫调节剂在抗呼吸道病毒感染中的潜力。

---

**注**：以上文献标题及作者为示例性内容，实际研究中请通过PubMed或Google Scholar以“IL28A recombinant protein”、“IFN-λ1 expression”等关键词检索具体文献。

背景信息

**Background of IL-IL28A (IFN-λ2) Recombinant Protein**

Interleukin-28A (IL-28A), also known as interferon lambda 2 (IFN-λ2), is a member of the type III interferon family, which includes IL-28A, IL-28B (IFN-λ3), and IL-29 (IFN-λ1). These cytokines share structural and functional similarities with type I interferons but signal through a distinct receptor complex composed of IL-10Rβ and IFN-λR1. IL-28A is primarily produced by immune cells (e.g., dendritic cells) and epithelial cells in response to viral infections or Toll-like receptor (TLR) activation.

The IL28A gene is located on chromosome 19 in humans and encodes a protein with antiviral, immunomodulatory, and antiproliferative properties. Its recombinant form is engineered using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Recombinant IL-28A activates the JAK-STAT signaling pathway, inducing interferon-stimulated genes (ISGs) that inhibit viral replication and enhance pathogen detection.

Unlike type I interferons, IL-28A exhibits tissue-specific activity, primarily targeting epithelial and hepatic cells due to restricted IFN-λR1 expression. This specificity reduces systemic side effects, making it a promising therapeutic candidate. Preclinical studies highlight its efficacy against hepatitis B/C viruses, respiratory viruses, and certain cancers. It also modulates adaptive immunity by enhancing antigen presentation and T-cell responses.

Current research focuses on optimizing IL-28A-based therapies, including pegylation to extend half-life and combination regimens with antivirals or checkpoint inhibitors. Challenges remain in understanding its dual role in inflammation and tissue repair, as well as its variable clinical responses across populations. Nonetheless, IL-28A represents a key player in bridging innate and adaptive immunity, offering potential for targeted antiviral and oncological applications.